104 related articles for article (PubMed ID: 38841622)
1. Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine.
Bajinka O; Ouedraogo SY; Golubnitschaja O; Li N; Zhan X
EPMA J; 2024 Jun; 15(2):289-319. PubMed ID: 38841622
[TBL] [Abstract][Full Text] [Related]
2. Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies.
Park JG; Choi BK; Lee Y; Jang EJ; Woo SM; Lee JH; Kim KH; Hwang H; Choi W; Lee SH; Yoo BC
EPMA J; 2021 Dec; 12(4):629-645. PubMed ID: 34956427
[TBL] [Abstract][Full Text] [Related]
3. The paradigm change from reactive medical services to 3PM in ischemic stroke: a holistic approach utilising tear fluid multi-omics, mitochondria as a vital biosensor and AI-based multi-professional data interpretation.
Golubnitschaja O; Polivka J; Potuznik P; Pesta M; Stetkarova I; Mazurakova A; Lackova L; Kubatka P; Kropp M; Thumann G; Erb C; Fröhlich H; Wang W; Baban B; Kapalla M; Shapira N; Richter K; Karabatsiakis A; Smokovski I; Schmeel LC; Gkika E; Paul F; Parini P; Polivka J
EPMA J; 2024 Mar; 15(1):1-23. PubMed ID: 38463624
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
Li N; Jia W; Wang J; Shao Q; Feng X; Li Z; Sun W; Kang M; Hu D; Xing L; Zhan X
EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant stratification of lung squamous carcinoma patients based on ubiquitinated proteasome genes for 3P medical approach.
Yang J; Ouedraogo SY; Wang J; Li Z; Feng X; Ye Z; Zheng S; Li N; Zhan X
EPMA J; 2024 Mar; 15(1):67-97. PubMed ID: 38463626
[TBL] [Abstract][Full Text] [Related]
6. Underexplored reciprocity between genome-wide methylation status and long non-coding RNA expression reflected in breast cancer research: potential impacts for the disease management in the framework of 3P medicine.
Kapinova A; Mazurakova A; Halasova E; Dankova Z; Büsselberg D; Costigliola V; Golubnitschaja O; Kubatka P
EPMA J; 2023 Jun; 14(2):249-273. PubMed ID: 37275549
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions.
Kucera R; Pecen L; Topolcan O; Dahal AR; Costigliola V; Giordano FA; Golubnitschaja O
EPMA J; 2020 Sep; 11(3):399-418. PubMed ID: 32843909
[TBL] [Abstract][Full Text] [Related]
8. Mini-encyclopedia of mitochondria-relevant nutraceuticals protecting health in primary and secondary care-clinically relevant 3PM innovation.
Golubnitschaja O; Kapinova A; Sargheini N; Bojkova B; Kapalla M; Heinrich L; Gkika E; Kubatka P
EPMA J; 2024 Jun; 15(2):163-205. PubMed ID: 38841620
[TBL] [Abstract][Full Text] [Related]
9. Nitroproteomics is instrumental for stratification and targeted treatments of astrocytoma patients: expert recommendations for advanced 3PM approach with improved individual outcomes.
Jia W; Gong X; Ye Z; Li N; Zhan X
EPMA J; 2023 Dec; 14(4):673-696. PubMed ID: 38094577
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine.
Zhan X; Li J; Guo Y; Golubnitschaja O
EPMA J; 2021 Dec; 12(4):449-475. PubMed ID: 34876936
[TBL] [Abstract][Full Text] [Related]
11. Anti-prostate cancer protection and therapy in the framework of predictive, preventive and personalised medicine - comprehensive effects of phytochemicals in primary, secondary and tertiary care.
Mazurakova A; Samec M; Koklesova L; Biringer K; Kudela E; Al-Ishaq RK; Pec M; Giordano FA; Büsselberg D; Kubatka P; Golubnitschaja O
EPMA J; 2022 Sep; 13(3):461-486. PubMed ID: 35821883
[TBL] [Abstract][Full Text] [Related]
12. Flavonoids against non-physiologic inflammation attributed to cancer initiation, development, and progression-3PM pathways.
Kubatka P; Mazurakova A; Samec M; Koklesova L; Zhai K; Al-Ishaq R; Kajo K; Biringer K; Vybohova D; Brockmueller A; Pec M; Shakibaei M; Giordano FA; Büsselberg D; Golubnitschaja O
EPMA J; 2021 Dec; 12(4):559-587. PubMed ID: 34950252
[TBL] [Abstract][Full Text] [Related]
13. Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework.
Liu J; Shi Y; Zhang Y
EPMA J; 2023 Jun; 14(2):275-305. PubMed ID: 37275552
[TBL] [Abstract][Full Text] [Related]
14. Machine learning-couched treatment algorithms tailored to individualized profile of patients with primary anterior chamber angle closure predisposed to the glaucomatous optic neuropathy.
Kurysheva NI; Rodionova OY; Pomerantsev AL; Sharova GA; Golubnitschaja O
EPMA J; 2023 Sep; 14(3):527-538. PubMed ID: 37605656
[TBL] [Abstract][Full Text] [Related]
15. Caution, "normal" BMI: health risks associated with potentially masked individual underweight-EPMA Position Paper 2021.
Golubnitschaja O; Liskova A; Koklesova L; Samec M; Biringer K; Büsselberg D; Podbielska H; Kunin AA; Evsevyeva ME; Shapira N; Paul F; Erb C; Dietrich DE; Felbel D; Karabatsiakis A; Bubnov R; Polivka J; Polivka J; Birkenbihl C; Fröhlich H; Hofmann-Apitius M; Kubatka P
EPMA J; 2021 Sep; 12(3):243-264. PubMed ID: 34422142
[TBL] [Abstract][Full Text] [Related]
16. Predictive, preventive and personalised approach as a conceptual and technological innovation in primary and secondary care of inflammatory bowel disease benefiting affected individuals and populations.
Arosa L; Camba-Gómez M; Golubnitschaja O; Conde-Aranda J
EPMA J; 2024 Mar; 15(1):111-123. PubMed ID: 38463620
[TBL] [Abstract][Full Text] [Related]
17. Digital biomarkers: 3PM approach revolutionizing chronic disease management - EPMA 2024 position.
Smokovski I; Steinle N; Behnke A; Bhaskar SMM; Grech G; Richter K; Niklewski G; Birkenbihl C; Parini P; Andrews RJ; Bauchner H; Golubnitschaja O
EPMA J; 2024 Jun; 15(2):149-162. PubMed ID: 38841615
[TBL] [Abstract][Full Text] [Related]
18. Quantitative phosphoproteomics reveals molecular pathway network alterations in human early-stage primary hepatic carcinomas: potential for 3P medical approach.
Zhang Y; Li N; Yang L; Jia W; Li Z; Shao Q; Zhan X
EPMA J; 2023 Sep; 14(3):477-502. PubMed ID: 37605650
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial health quality control: measurements and interpretation in the framework of predictive, preventive, and personalized medicine.
Koklesova L; Mazurakova A; Samec M; Kudela E; Biringer K; Kubatka P; Golubnitschaja O
EPMA J; 2022 Jun; 13(2):177-193. PubMed ID: 35578648
[TBL] [Abstract][Full Text] [Related]
20. miR-495-3p regulates sphingolipid metabolic reprogramming to induce Sphk1/ceramide mediated mitophagy and apoptosis in NSCLC.
Arora S; Singh P; Tabassum G; Dohare R; Syed MA
Free Radic Biol Med; 2022 Aug; 189():71-84. PubMed ID: 35853537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
